Sleep isn’t a nightly reboot so much as an orchestra—slow waves, REM crescendos, and circadian timing keeping the beat. With age, instruments drop out and the conductor drifts. Sleep becomes lighter and more fragmented; circadian rhythms flatten; comorbidities pile on; medications nudge physiology off-key. That drift isn’t just an inconvenience. In late life, how—and whether—we sleep reverberates across cardiovascular risk, metabolic control, immune function, cognition, frailty, and ultimately mortality.

Two disorders dominate the stage: insomnia (difficulty initiating or maintaining sleep with daytime consequences) and obstructive sleep apnea (repeated airway collapse leading to intermittent hypoxia and arousals). They often co-occur, complicating care and magnifying risk. The question for longevity is direct: do these conditions shorten life, and can treating them bend the curve?

Insomnia: When Sleepless Nights Echo Into Daylight

Insomnia prevalence climbs with age, and its link to mortality has been debated for years. Newer, older-adult–focused cohorts are clarifying the picture. A 2024 analysis reported that clinical insomnia in later life is associated with a higher risk of all-cause mortality and non-fatal cardiovascular events, even after adjusting for confounders—evidence that persistent, symptomatic insomnia isn’t benign in old age.

Converging work in older cohorts has parsed which insomnia features matter. In a longitudinal study of adults ≥65, both nighttime insomnia symptoms (sleep-onset, maintenance, early awakenings) and daytime sequelae (fatigue, poor concentration) tracked with higher all-cause mortality over long follow-up, suggesting that the “tired but wired” phenotype carries the greatest risk signal.

What’s the mechanism? Fragmented, insufficient, or mistimed sleep amplifies sympathetic tone, blood pressure lability, insulin resistance, and systemic inflammation; it also erodes slow-wave sleep needed for glymphatic clearance and memory consolidation. Large, mixed-age meta-analyses show the familiar U- or J-shaped curve: short and long sleep relate to higher mortality, with optimal in the ~6–8 hour range—an effect that persists in older groups, albeit with shape nuances by age.

Sleep Apnea: The Stop-Start Heartache

OSA prevalence rises steeply in later life due to anatomical changes, weight gain, and reduced airway tone. Its physiologic triad—intermittent hypoxia, arousals, and intrathoracic pressure swings—drives hypertension, atrial remodeling, insulin resistance, dyslipidemia, and endothelial dysfunction. Recent population-level and disease-specific analyses in 2024–2025 reinforce that OSA is linked to higher cardiovascular events and mortality, with particularly worrying signals for sudden cardiac death in those with severe disease.

Notably, sleep need and breathing stability interact: in a large cohort, people with OSA who slept <7 hours had significantly higher all-cause mortality, independent of apnea severity. Short sleep seems to potentiate the harm of respiratory events—less room to recover, more sympathetic load.

Treatment and Longevity: What Actually Moves the Needle?

Positive Airway Pressure (PAP/CPAP)

The purest test is whether treatment lowers deaths and major events. Randomized trials powered for hard outcomes are hard to run (adherence is the Achilles’ heel), but the totality of evidence is sharpening. A 2025 systematic review and meta-analysis in The Lancet Respiratory Medicine found that PAP therapy is associated with reduced all-cause and cardiovascular mortality in OSA, especially when adherence is adequate. This aligns with real-world data from ~889,000 Medicare beneficiaries showing lower mortality and fewer major adverse cardiovascular events among those initiating PAP vs. non-users.

Randomized trials in acute coronary syndrome populations have been more equivocal on recurrent events unless adherence is high, but pooled analyses underscore the same lesson: consistent nightly use matters. Longevity, here, looks less like a switch and more like a dose-response curve.

A New Pharmacologic Era for OSA

December 20, 2024 marked a milestone: the FDA approved tirzepatide (Zepbound) as the first medication for moderate-to-severe OSA in adults with obesity, alongside diet and activity. In 52-week trials, tirzepatide reduced apnea events and led to substantial weight loss; in some analyses, up to ~52% achieved OSA resolution depending on study arm and definition. For older adults with obesity who cannot tolerate PAP, or as an adjunct to PAP, this expands the therapeutic playbook in a way that plausibly improves long-term outcomes via combined weight loss, blood pressure improvements, and hypoxia reduction.

(Important nuance for clinicians and public health: despite OSA’s prevalence, the USPSTF still finds insufficient evidence to screen asymptomatic adults, so case-finding hinges on risk factors and symptoms rather than universal screening programs.)

Insomnia Care That Extends Healthspan

For chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment per the American Academy of Sleep Medicine. Access barriers have spurred digital CBT-I platforms; while face-to-face and telehealth CBT-I still show larger effects, structured digital programs can be a practical on-ramp, particularly for older adults juggling mobility and caregiving constraints. Pharmacologic options exist but are second-line and require caution in late life due to falls and cognitive side effects.

The Brain’s Night Watch: Sleep, Amyloid, and Cognitive Trajectories

The brain’s housekeeping—glymphatic flux, synaptic down-selection—leans on consolidated slow-wave sleep and stable circadian rhythms. In cognitively normal older adults, sleep fragmentation and weaker 24-hour activity rhythms precede amyloid-β deposition, suggesting that circadian-sleep disruption is not just epiphenomenon but a potential early driver of Alzheimer’s biology. Objective metrics (efficiency, WASO, fragmentation) correlate with regional cortical thinning in AD-vulnerable cortices, and multiple studies tie lighter, more fragmented sleep to greater amyloid and tau burden across plasma, CSF, and PET modalities. These links strengthen the case that stabilizing sleep architecture is a legitimate target for preserving cognitive healthspan.

Frailty, Metabolism, and the Slow Creep of Biological Age

Sleep duration and quality also map onto frailty—a clinical shorthand for multisystem physiological reserve. In a large Chinese cohort aged ≥45, short sleep increased frailty risk, implying that extending and consolidating sleep may delay the shift from robustness to vulnerability. At the population level, imbalanced sleep (too little or too much) elevates mortality risk, with sex-specific nuances. For older adults navigating sarcopenia, insulin resistance, and polypharmacy, even small improvements in sleep can ripple across strength, balance, and glucose control.

What This Means for Longevity—A Practical, Evidence-Anchored Map

The horizon has moved. We used to treat late-life sleep complaints as inevitable background noise. The new evidence says some of that noise is a signal you can act on.

For obstructive sleep apnea: prioritize accurate diagnosis when symptoms or risk are present; aim for adherent PAP (track nightly hours); consider tirzepatide when obesity is part of the phenotype and goals include weight loss plus OSA control; layer in positional therapy, oral appliances, myofunctional therapy, and (select cases) airway surgery. The combination that reduces hypoxic burden most reliably is the one that will likely matter for long-term outcomes.

For insomnia: use CBT-I first—optimize stimulus control, sleep restriction with careful late-life tailoring, and cognitive strategies that quiet the pre-sleep mind. Digital CBT-I is better than waiting months to start; transition to therapist-guided care when possible. Treat comorbid mood disorders and pain, review medications that fragment sleep (late-day diuretics, activating antidepressants), and keep pharmacologic hypnotics as short-term bridges rather than lifestyle.

For cognition and circadian health: protect slow-wave sleep and rhythm regularity—consistent bed and rise times, daylight in the morning, dimmer evenings, activity during the day. These low-tech maneuvers align neuronal housekeeping with the clockwork your brain still keeps, even if the ticks are softer than before.

A Closer Look at the Data: Concrete Results Worth Knowing

• In a Medicare cohort of 888,835 older adults with OSA, initiating PAP was associated with lower all-cause mortality and fewer major adverse cardiovascular events than no therapy. Real-world scale, real-world benefit.
• A 2025 meta-analysis spanning multiple studies concluded that PAP use reduces all-cause and cardiovascular mortality in OSA, especially with better adherence—support that the therapy’s physiological logic translates into survival curves.
• The FDA approved tirzepatide for moderate-to-severe OSA with obesity (Dec 2024), after trials in which up to ~52% of participants met resolution criteria depending on arm and definition, and apnea events dropped by ~55–63% on-drug. Weight loss was substantial and likely contributed, but respiratory metrics improved directly.
• In older-adult cohorts, insomnia correlated with higher mortality and non-fatal cardiovascular events, particularly when daytime impairment accompanied nighttime symptoms, underscoring that “just a bit of bad sleep” in late life can have systemic consequences.
• Circadian rhythm instability and sleep fragmentation predicted amyloid-β deposition in cognitively normal elders—an ominous biomarker trajectory that points to prevention via rhythm repair.

Background, Decoded: How Sleep Loss Ages the Body

Think of sleep fragmentation as micro-trauma repeated hundreds of times nightly. Each arousal spikes catecholamines and blood pressure. Over years, that pulsatile stress stiffens arteries, perturbs baroreflexes, and prompts atrial remodeling—fertile ground for hypertension and atrial fibrillation, which then boomerang back to worsen sleep. OSA adds intermittent hypoxia, which toggles HIF pathways, increases oxidative stress, and destabilizes plaques. Insomnia, especially with objectively short sleep, sustains sympathetic overdrive, insulin resistance, and systemic inflammation while robbing the brain of slow-wave-enabled memory consolidation and metabolic housekeeping. The result is a multisystem nudge toward frailty, metabolic syndrome, cognitive decline, and earlier mortality.

The Gentle Art of Adding Years to Life (and Life to Years)

The longevity play here isn’t exotic. It is disciplined and cumulative:

• Identify OSA when likely (snoring, witnessed apneas, resistant hypertension, atrial fibrillation, sleepiness, morning headaches). If diagnosed, treat it and measure adherence; iterate until nightly hours are consistently therapeutic. Consider tirzepatide if obesity and OSA travel together and goals include sustained weight loss with apnea control.
• Treat chronic insomnia with CBT-I rather than defaulting to sedative pharmacology. Start digitally if access is limited; scale to therapist-guided care. Guard rail with fall-risk assessments and medication reviews.
• Rebuild circadian amplitude: bright morning light, consistent daytime activity, regular meal timing, and a quiet, dim evening. These are small levers that move big biology in older adults.

Sleep in late life isn’t a lost cause; it’s a modifiable system hiding in plain sight. For insomnia and OSA, the science now reads like a longevity manual: fix the night to save the day—and, very possibly, to add more of them.

References

1. Benjafield, A. V., Pépin, J.-L., Cistulli, P. A., Wimms, A., Lavergne, F., Sert Kuniyoshi, F. H., … Malhotra, A. (2025). Positive airway pressure therapy and all-cause and cardiovascular mortality in people with obstructive sleep apnoea: A systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies. The Lancet Respiratory Medicine, 13(5), 403–413. https://doi.org/10.1016/S2213-2600(25)00002-5
2. Huang, Q.-M., Yan, H.-Y., Chen, H., Xie, J.-H., Gao, J., Li, Z.-H., & Mao, C. (2025). Insomnia symptom trajectories and incident cardiovascular disease in older adults: A longitudinal cohort study. Heart. Advance online publication. https://doi.org/10.1136/heartjnl-2024-325362
3. Jin, Q., Fan, T., Lin, H., Xu, L., Li, W., Zhang, M., … Guo, X. (2022). Association of sleep duration with all-cause and cardiovascular mortality and incident cardiovascular disease. Frontiers in Public Health, 10, 880276. https://doi.org/10.3389/fpubh.2022.880276
4. Lin, Y., Patel, S. R., Redline, S., … Quan, S. F. (2023). Objective sleep duration and all-cause mortality among people with obstructive sleep apnea. JAMA Network Open. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2812565
5. Mazzotti, D. R., Patel, S. R., Bena, J. F., … Quan, S. F. (2024). Positive airway pressure, mortality, and cardiovascular risk in older adults with sleep apnea. JAMA Network Open. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823539
6. Starling, C. M., Greenberg, D., Lewin, D., Zhou, E. S., Lieberman, D., Chou, J., … Arem, H. (2024). Voice-activated cognitive behavioral therapy for insomnia: A randomized clinical trial. JAMA Network Open, 7(9), e2435011. https://doi.org/10.1001/jamanetworkopen.2024.35011
7. Ungvari, Z., Fehér, A., Kókai, E., … Tarantini, S. (2025). Imbalanced sleep increases mortality risk by 14–34%: A meta-analysis. GeroScience. https://doi.org/10.1007/s11357-025-01592-y
8. Windred, D. P., Kaplan, K. A., Reynolds, A. C., Naismith, S. L., Ksendzovsky, A., Murray, J. M., … Bei, B. (2024). Sleep regularity is a stronger predictor of mortality risk than sleep duration: A prospective cohort study. Sleep, 47(1), zsad253. https://doi.org/10.1093/sleep/zsad253
9. Zhang, Y., Chen, H., Tang, Z., Sun, F., Wang, Y., & Lyu, J. (2024). The relationship between sleep duration and frailty: Evidence from cross-sectional and longitudinal analyses of middle-aged and older adults. Frontiers in Public Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC11701061/
10. Yin, J., Jin, X., Shan, Z., Li, S., Huang, H., Li, P., … Liu, L. (2017). Relationship of sleep duration with all-cause mortality and cardiovascular events: A systematic review and dose-response meta-analysis of prospective cohort studies. Journal of the American Heart Association, 6(9), e005947. https://doi.org/10.1161/JAHA.117.005947
11. Sherwood, A., Ulmer, C., Wu, J. Q., Blumenthal, J. A., Herold, E., Smith, P. J., … Hinderliter, A. (2024). Cognitive behavior therapy for insomnia for untreated hypertension with comorbid insomnia disorder: The SLEEPRIGHT clinical trial. Journal of Clinical Hypertension, 26(4), 441–447. https://doi.org/10.1111/jch.14763